Eagle’s Eye View: What is the Long-Term Mortality of Patients With Ebstein Anomaly?

In this week’s View, Dr. Eagle explores the long-term mortality of patients with Ebstein Anomaly. He then discusses a study that looks at the modifiability of cardiovascular risk associated with chronic kidney disease in patients with type 2 diabetes treated with finerenone. Finally, Dr. Eagle looks at the effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations.

Twitter Links:

Clinical Topics: Cardiac Surgery, Congenital Heart Disease and Pediatric Cardiology, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Cardiac Surgery and Arrhythmias, Cardiac Surgery and CHD and Pediatrics, Cardiac Surgery and Heart Failure, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Interventions, CHD and Pediatrics and Prevention, Lipid Metabolism, Acute Heart Failure, Interventions and Structural Heart Disease, Acute Coronary Syndromes, Cardiovascular Care Team

Keywords: Cardiac Surgical Procedures, Ebstein Anomaly, Heart Defects, Congenital, Pediatrics, Tricuspid Valve, Univentricular Heart, Acute Kidney Injury, Albumins, Albuminuria, Angiotensins, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Heart Failure, Metabolic Syndrome, Mineralocorticoid Receptor Antagonists, Myocardial Infarction, Myocardial Ischemia, Hospitalization, Primary Prevention, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Sodium-Glucose Transporter 2, Stroke Volume, Vascular Diseases, EaglesEyeView

< Back to Listings